View Exam | PowerPak

1. Which of the following cytokines are implicated in the pathogenesis of AD?

A. IL-4 B. IL-31 C. IL-5 D. All of the above

2. Which of the following signaling molecules plays a key role in the positive feedback loop facilitated by the JAK-STAT pathway in AA?

A. IL-13 B. IL-4 C. Interferon-? D. Transforming growth factor-β

3. Which of the following has been shown to be true regarding the efficacy of oral and topical JAK-STAT inhibitors for AD and AA?

A. Both oral and topical formulations are effective B. Neither oral nor topical formulations are effective C. Oral formulations are effective but topical formulations are not D. Topical formulations are effective but oral formulations are not

4. A 31-year-old patient with a history of severe AA involving the majority of her scalp presents for treatment after failing to respond to contact sensitization and topical therapy. Her provider prescribes her off-label oral JAK-STAT inhibitors. Which one of the following is an adverse effect that should be discussed with the patient?

A. Arthralgia B. Insulin resistance C. Paradoxical hair loss D. Serious infections

5. A patient with severe AD has not responded to treatment with topical corticosteroids and was recently prescribed biologic therapy. At the time of treatment initiation, which one of the following interventions can be undertaken by the pharmacist to improve outcomes for this patient?

A. Clinical assessment B. Discussing recommendations for treatment switching C. Pretreatment immunization D. Training medication administration techniques

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following cytokines are implicated in the pathogenesis of AD?

2. Which of the following signaling molecules plays a key role in the positive feedback loop facilitated by the JAK-STAT pathway in AA?

3. Which of the following has been shown to be true regarding the efficacy of oral and topical JAK-STAT inhibitors for AD and AA?

5. A patient with severe AD has not responded to treatment with topical corticosteroids and was recently prescribed biologic therapy. At the time of treatment initiation, which one of the following interventions can be undertaken by the pharmacist to improve outcomes for this patient?

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following cytokines are implicated in the pathogenesis of AD?

2. Which of the following signaling molecules plays a key role in the positive feedback loop facilitated by the JAK-STAT pathway in AA?

3. Which of the following has been shown to be true regarding the efficacy of oral and topical JAK-STAT inhibitors for AD and AA?

5. A patient with severe AD has not responded to treatment with topical corticosteroids and was recently prescribed biologic therapy. At the time of treatment initiation, which one of the following interventions can be undertaken by the pharmacist to improve outcomes for this patient?

« Return to Activity

Customers who Purchased
this Activity also Purchased